查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1815336

標靶放射性藥物市場報告：2031 年趨勢、預測與競爭分析

Targeted Radiopharmaceutical Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球標靶放射性藥物市場前景光明，標靶治療和標靶診斷市場蘊藏著巨大機會。預計2025年至2031年，全球標靶放射性藥物市場將以14.4%的複合年成長率成長。癌症和心血管疾病發生率的上升以及人口老化是推動該市場成長的關鍵因素。

  • Lucintel 預測，利用放射性物質選擇性地瞄準和治療癌細胞和其他患病組織的標靶治療將在預測期內實現高速成長。
  • 從應用角度來看，標靶治療有望因前列腺癌、神經內分泌腫瘤和淋巴瘤的有效治療而實現高速成長。
  • 按地區分類，預計北美將在預測期內實現最高成長。

靶向放射性藥物市場的新趨勢

靶向放射性藥物市場受到多種新興趨勢的影響，這些趨勢將決定其未來的成長。這些趨勢包括技術進步、監管變化以及個人化醫療日益成長的重要性。隨著產業的不斷發展，這些趨勢不僅會影響治療效果，還會影響新產品的上市方式以及與醫療保健系統的整合。

  • 治療診斷學日益受到關注：治療診斷學結合了診斷和治療放射性藥物，是一個快速發展的趨勢。這種方法能夠利用放射性同位素精準靶向癌細胞，從而製定個人化治療方案。同時診斷和治療可提高療效並減少副作用。這一趨勢在腫瘤學領域尤為明顯，用於前列腺癌的Pluvicto和镥-177等放射性藥物既用於成像，也用於治療，推動了市場的顯著成長。
  • 人工智慧與機器學習的融合：人工智慧和機器學習正日益應用於放射性藥物的開發。這些技術透過預測放射性藥物的療效和毒性特徵，幫助最佳化其設計。人工智慧工具也正在簡化放射性藥物的生產流程，降低成本並提高準確性。這種融合在確定最佳劑量和患者特異性治療方法尤其有用，最終將推動個人化醫療的發展，並減少放射治療相關的副作用。
  • 標靶治療的擴展：癌症仍是標靶放射性藥物的主要治療目標，許多研發成果旨在改善治療效果。由於用於治療神經內分泌腫瘤等難治性癌症的放射性藥物數量不斷增加，標靶癌症治療市場正在不斷擴大。諸如α粒子療法之類的技術創新，能夠將輻射更局部地輸送到癌細胞，正日益受到關注。癌症發生率的上升以及對更有效、微創治療的需求不斷成長，推動了靶向放射性藥物市場的發展，使其成為癌症治療的重要工具。
  • 監管進展和核准流程：監管機構，尤其是美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA)，正在簡化放射性藥物的核准流程，以促進新療法更快進入市場。例如，美國食品藥物管理局 (FDA) 正在為放射性藥物的核准提供更靈活的途徑，以加速救命療法的核准流程。這一趨勢不僅縮短了從研究到患者用藥的時間，也鼓勵了放射性藥物設計的創新。預計更強力的監管支持將增強市場信心，並進一步推動這些療法在全球範圍內的應用。
  • 全球合作與研究計劃：放射性藥物的開發由各國和各研究機構之間的合作所推動。大學、生技公司和醫療保健組織之間的官民合作關係關係正在加速創新。國際研究聯盟正在開發新的同位素，改進生產技術，並更好地了解放射性藥物在不同患者群體中的有效性。這種全球合作模式正在培育更多樣化的放射性藥物產品線，確保世界各地的患者都能從尖端治療中受益。

這些趨勢正在重塑針對放射性藥物市場，推動創新，改善患者療效，並降低治療成本。人工智慧、監管進步和全球合作的融合正在加速標靶治療的開發和普及，尤其是在腫瘤領域。隨著市場的成長，這些趨勢將繼續最佳化個人化、精準治療的交付，最終改變癌症和其他複雜疾病的醫療保健模式。

靶向放射性藥物市場的最新發展

從監管突破到技術創新，近期的幾大趨勢正在改變標靶放射性藥物市場。這些發展正在提高放射性藥物治療的精準度、可用性和療效，為改善患者治療效果和促進市場成長鋪平道路。

  • FDA核准Pluvicto：Pluvicto (177Lu-PSMA-617) 用於治療攝護腺癌，核准標靶放射性藥物在腫瘤治療領域的重大里程碑。這種新型療法將放射性粒子與特異性靶向前列腺癌細胞的分子結合，從而減少對健康組織的損害。 FDA核准是前列腺癌領域首個此類藥物，為晚期癌患者帶來了新的希望。這項進展為癌症治療的進一步創新打開了大門，尤其是針對具有特定分子標靶的癌症。
  • 阿爾法粒子療法的發展：阿爾法粒子療法，例如錒-225和鐳-223，已成為治療多種癌症的有前景的療法。這些療法能夠提供高度局部的輻射，最大限度地減少對周圍健康組織的損傷，並代表了一種治療對傳統療法抗藥性的腫瘤的新方法。隨著阿爾法粒子療法研究的不斷發展，靶向放射性藥物市場預計將出現顯著成長，尤其是在轉移性癌症的治療方面。
  • 影像和診斷技術的進步：PET 和 SPECT 等分子成像技術的進步顯著提高了標靶放射性藥物的精準度。這些成像技術能夠即時監測放射性藥物的分佈和效應，從而將放射性藥物精準地輸送至病灶。這項發展對個人化醫療具有重要意義，個人化醫療可以根據影像學結果量身訂做治療方案，以最大限度地提高治療效果。
  • 生物技術-製藥夥伴關係：生物技術公司與大型製藥公司之間的策略夥伴關係正在加速靶向放射性藥物的開發。例如，旨在開發用於癌症治療的新型放射性標記抗體的合作正在拓展標靶治療的潛力。此類合作促進了資源、專業知識和臨床數據的共用，最終加速了創新放射性藥物的商業化。
  • 擴大放射性同位素產能：為了滿足日益成長的靶向放射性藥物需求，各公司正在擴大關鍵放射性同位素的產能，包括Technetium-99m、鎦-177和碘-131。此次擴產旨在應對供應鏈挑戰，並確保臨床所需的同位素供應充足。隨著製造技術的進步，放射性藥物的生產成本預計將下降，使更多患者能夠獲得這些治療。

這些關鍵進展正在透過改善治療的可及性、有效性和精準度，徹底改變靶向放射性藥物市場。 FDA 的核准、α粒子療法的進步以及行業相關人員之間不斷擴大的夥伴關係關係，正在創造新的成長機會。隨著產能的不斷擴大和新技術的湧現，靶向放射性藥物市場有望持續創新，並在全球醫療保健領域發揮更重要的作用。

目錄

第1章執行摘要

第2章 市場概況

  • 背景和分類
  • 供應鏈

第3章：市場趨勢及預測分析

  • 宏觀經濟趨勢與預測
  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球標靶放射性藥物市場（按類型）

  • 概述
  • 按類型進行吸引力分析
  • 標靶治療：趨勢與預測（2019-2031）
  • 標靶診斷：趨勢與預測（2019-2031）

5. 全球標靶放射性藥物市場（依應用）

  • 概述
  • 按用途進行吸引力分析
  • 標靶治療：趨勢與預測（2019-2031）
  • 標靶診斷：趨勢與預測（2019-2031）

第6章區域分析

  • 概述
  • 區域目標放射性藥物市場

7. 北美標靶放射性藥物市場

  • 概述
  • 美國目標放射性藥物市場
  • 墨西哥的目標放射性藥物市場
  • 加拿大靶向放射性藥物市場

8. 歐洲目標放射性藥物市場

  • 概述
  • 德國目標放射性藥物市場
  • 法國目標放射性藥物市場
  • 西班牙目標放射性藥物市場
  • 義大利目標放射性藥物市場
  • 英國瞄準放射性藥物市場

9. 亞太地區標靶放射性藥物市場

  • 概述
  • 日本的目標放射性藥物市場
  • 印度的目標放射性藥物市場
  • 中國標靶放射性藥物市場
  • 韓國靶向放射性藥物市場
  • 印尼的目標放射性藥物市場

10. 其他地區針對放射性藥物市場

  • 概述
  • 中東目標放射性藥物市場
  • 南美洲靶向放射性藥物市場
  • 非洲標靶放射性藥物市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市佔率分析

第12章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 按應用分類的成長機會
  • 全球靶向放射性藥物市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 合併、收購、協議、合作和合資企業

第13章 價值鏈主要企業的公司簡介

  • 競爭分析
  • Novartis
  • Bayer
  • Lantheus
  • Institute For Radioelements
  • Radiomedix
  • Curium Pharma
  • Clarity Pharmaceuticals

第14章 附錄

  • 圖表目錄
  • 表格一覽
  • 調查方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於我們
  • 聯絡處

The future of the global targeted radiopharmaceutical market looks promising with opportunities in the targeted therapy and targeted diagnosis markets. The global targeted radiopharmaceutical market is expected to grow with a CAGR of 14.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of cancer & cardiovascular disease and the growing aging population.

  • Lucintel forecasts that, within the type category, targeted therapeutic is expected to witness higher growth over the forecast period due to use radioactive substances to selectively target and treat cancer cells or other disease tissues.
  • Within the application category, targeted therapy is expected to witness the higher growth due to effective treatment of cancers such as prostate cancer, neuroendocrine tumors, and lymphoma.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Targeted Radiopharmaceutical Market

The targeted radiopharmaceutical market is influenced by several emerging trends, shaping its future growth. These trends include technological advancements, regulatory changes, and the increasing importance of personalized medicine. As the industry continues to evolve, these trends not only impact treatment efficacy but also the ways in which new products are brought to market and integrated into healthcare systems globally.

  • Increased Focus on Theranostics: Theranostics, the combination of diagnostic and therapeutic radiopharmaceuticals, is a rapidly growing trend. This approach allows for precise targeting of cancer cells with radioactive isotopes, enabling personalized treatment plans. The ability to diagnose and treat simultaneously enhances treatment efficacy and reduces side effects. This trend is particularly prominent in oncology, where radiopharmaceuticals like Pluvicto for prostate cancer and Lutetium-177 are being used for both imaging and therapy, driving significant market growth.
  • Integration of AI and Machine Learning: AI and machine learning are increasingly being applied to radiopharmaceutical development. These technologies help optimize the design of radiopharmaceuticals by predicting their effectiveness and toxicity profiles. AI-driven tools are also streamlining the radiopharmaceutical manufacturing process, reducing costs and improving precision. This integration is particularly valuable in identifying optimal dosages and patient-specific treatment regimens, ultimately advancing personalized medicine and reducing adverse effects associated with radiation therapy.
  • Expansion of Targeted Cancer Therapies: Cancer remains the primary therapeutic focus for targeted radiopharmaceuticals, with numerous developments aimed at improving treatment outcomes. The rise of radiopharmaceuticals for hard-to-treat cancers, such as neuroendocrine tumors, has expanded the market. Innovations like alpha-particle therapies, which deliver more localized radiation to cancer cells, are gaining attention. This expansion is supported by increasing cancer prevalence and the growing demand for more effective, less invasive treatments, positioning radiopharmaceuticals as key tools in oncology.
  • Regulatory Advancements and Approval Process: Regulatory bodies, particularly the FDA and EMA, are streamlining the approval process for radiopharmaceuticals, facilitating quicker market access for new treatments. The U.S. FDA, for example, has provided more flexible pathways for radiopharmaceutical approval, expediting the process for life-saving treatments. This trend is not only reducing the time from research to patient but also fostering innovation in radiopharmaceutical design. Stronger regulatory support is expected to enhance market confidence and further drive the adoption of these therapies globally.
  • Global Collaboration and Research Initiatives: Collaborative research efforts between countries and institutions are boosting radiopharmaceutical development. Public-private partnerships, such as those between universities, biotech companies, and healthcare organizations, are accelerating innovation. International research consortia are working on developing novel isotopes, improving production techniques, and enhancing the understanding of radiopharmaceuticals' effectiveness across different patient populations. This global approach is fostering a more diverse pipeline of radiopharmaceuticals, ensuring that patients worldwide benefit from cutting-edge treatments.

These trends are reshaping the targeted radiopharmaceutical market by driving innovation, improving patient outcomes, and reducing treatment costs. The convergence of AI, regulatory advancements, and global collaboration is accelerating the development and availability of targeted therapies, particularly in oncology. As the market grows, these trends will continue to optimize the delivery of personalized, precision-based treatments, ultimately transforming the healthcare landscape for cancer and other complex diseases.

Recent Developments in the Targeted Radiopharmaceutical Market

Several recent developments are transforming the targeted radiopharmaceutical market, from regulatory breakthroughs to technological innovations. These developments are enhancing the precision, availability, and effectiveness of radiopharmaceutical treatments, paving the way for improved patient outcomes and greater market growth.

  • FDA Approval of Pluvicto: The approval of Pluvicto (177Lu-PSMA-617) for prostate cancer represents a major milestone for targeted radiopharmaceuticals in oncology. This novel therapy combines a radioactive particle with a molecule that targets prostate cancer cells specifically, reducing damage to healthy tissues. The FDA's approval marks the first of its kind for prostate cancer, offering new hope for patients with advanced stages of the disease. This development opens the door for further innovations in cancer therapies, particularly for cancers with specific molecular targets.
  • Development of Alpha-Particle Therapies: Alpha-particle therapies, such as Actinium-225 and Radium-223, have emerged as promising treatments for various cancers. These therapies deliver highly localized radiation, minimizing damage to surrounding healthy tissue and providing a new approach for treating tumors that are resistant to traditional therapies. As research into alpha-particle therapy continues to evolve, the targeted radiopharmaceutical market is expected to see significant growth, especially in the treatment of metastatic cancers.
  • Technological Advancements in Imaging and Diagnostics: Advancements in molecular imaging technologies, such as PET and SPECT, have significantly improved the precision of targeted radiopharmaceuticals. These imaging techniques allow for real-time monitoring of the distribution and effectiveness of radiopharmaceuticals, ensuring that they are precisely targeted to the disease site. This development has major implications for personalized medicine, where treatments can be tailored based on the imaging results to maximize therapeutic outcomes.
  • Partnerships Between Biotech and Pharmaceutical Companies: Strategic partnerships between biotech firms and major pharmaceutical companies are accelerating the development of targeted radiopharmaceuticals. For instance, collaborations aimed at developing new radiolabeled antibodies for cancer therapy are pushing the boundaries of what is possible in targeted treatments. These alliances allow for sharing resources, expertise, and clinical data, ultimately speeding up the commercialization of innovative radiopharmaceuticals.
  • Expanding Production Capacity for Radioisotopes: To meet the growing demand for targeted radiopharmaceuticals, companies are expanding their production capabilities for key radioisotopes, such as Technetium-99m, Lutetium-177, and Iodine-131. This expansion is addressing supply chain challenges and ensuring that sufficient quantities of isotopes are available for clinical use. As production technologies improve, the cost of manufacturing radiopharmaceuticals is expected to decrease, making these therapies more accessible to a broader patient population.

These key developments are revolutionizing the targeted radiopharmaceutical market by improving the accessibility, effectiveness, and precision of treatments. The FDA approvals, advancements in alpha-particle therapies, and growing partnerships between industry players are creating new opportunities for growth. As production capabilities expand and new technologies emerge, the market is poised for continued innovation and a more significant role in global healthcare.

Strategic Growth Opportunities in the Targeted Radiopharmaceutical Market

Targeted radiopharmaceuticals offer significant growth opportunities across various applications. The market is evolving with an increasing focus on oncology, neurology, and diagnostic imaging, driven by both technological advancements and growing patient demand for more personalized treatments.

  • Oncology Treatments: Oncology is the largest application for targeted radiopharmaceuticals, and it continues to see the most significant growth. The development of radiopharmaceuticals targeting specific tumor types, such as Lutetium-177 for prostate cancer, is transforming cancer treatment by enabling targeted therapies that reduce damage to healthy tissue. With increasing cancer incidence, the market for radiopharmaceuticals in oncology is expected to expand rapidly, creating opportunities for both new entrants and established companies to innovate.
  • Neurology and Neurodegenerative Diseases: Targeted radiopharmaceuticals are increasingly being explored for neurological applications, particularly for neurodegenerative diseases like Alzheimer's. The development of PET radiopharmaceuticals to detect amyloid plaques is already making strides in diagnosis. As research progresses, there is potential for therapeutic radiopharmaceuticals that can target and treat these diseases at the molecular level. This expanding area offers new growth opportunities as the aging population increases globally.
  • Cardiology Applications: Radiopharmaceuticals are being developed for the diagnosis and treatment of cardiovascular diseases, such as atherosclerosis. For example, Thallium-201 is already used in cardiac imaging, but new developments are exploring radiopharmaceuticals for targeting heart tissue directly. As cardiovascular disease remains one of the leading causes of death worldwide, targeted radiopharmaceuticals offer significant potential for diagnostic imaging and therapy, especially in personalized treatment approaches.
  • Theranostic Applications: The combination of therapy and diagnostics into a single radiopharmaceutical, or theranostics, is gaining traction. By using the same agent for both diagnosis and treatment, theranostics allows for more personalized and precise interventions. This growing segment is driving innovations in oncology and other therapeutic areas, creating substantial growth opportunities as more personalized treatment regimens become available.
  • Expansion into Emerging Markets: Emerging markets, particularly in Asia and Latin America, are expected to see strong growth in the targeted radiopharmaceutical sector due to increasing healthcare investments and the rising incidence of cancer. As these markets develop their healthcare infrastructure, the demand for advanced therapies like targeted radiopharmaceuticals is expected to rise significantly. Companies entering these markets early can establish a competitive advantage by providing cost-effective solutions tailored to local healthcare needs.

These growth opportunities are transforming the targeted radiopharmaceutical market by expanding its application base and addressing diverse healthcare needs. From oncology to neurology and emerging markets, the opportunities for innovation and growth are vast. As these opportunities are realized, the market for targeted radiopharmaceuticals is poised to experience robust expansion across multiple therapeutic areas, benefiting patients globally.

Targeted Radiopharmaceutical Market Driver and Challenges

The targeted radiopharmaceutical market is shaped by a combination of technological advances, regulatory changes, economic factors, and market demand. However, these factors present both opportunities and challenges, requiring companies to adapt to evolving conditions while continuing to innovate in the development of new therapies. These drivers and challenges are interconnected and must be addressed to ensure the continued success of the market.

The factors responsible for driving the targeted radiopharmaceutical market include:

1. Technological Advancements: Recent technological innovations in imaging and radiopharmaceutical design are one of the major drivers of the market. Advances in PET and SPECT imaging technologies have enabled precise targeting and tracking of radiopharmaceuticals, ensuring higher treatment accuracy and lower side effects. New isotopes and alpha-particle therapies further expand the possibilities for treating cancer and other diseases. These advancements drive demand for more targeted and personalized treatment options.

2. Increasing Cancer Incidence: The global rise in cancer incidence is one of the key drivers behind the growth of the radiopharmaceutical market. As cancer rates continue to climb, especially in developed countries, the demand for more effective and less invasive treatments is accelerating. Targeted radiopharmaceuticals offer the potential to treat cancers more precisely, reducing side effects and improving outcomes, which makes them an attractive alternative to traditional therapies.

3. Regulatory Support and Approvals: The increasing support from regulatory bodies like the FDA and EMA is crucial in accelerating the adoption of targeted radiopharmaceuticals. Streamlined approval processes and flexible regulatory pathways are allowing new treatments to reach the market more quickly. This regulatory support is helping to drive innovation by encouraging pharmaceutical companies to invest more heavily in the development of novel radiopharmaceuticals.

4. Personalized Medicine Trends: The growing shift toward personalized medicine is a significant market driver. Radiopharmaceuticals allow for tailored treatments based on an individual's unique genetic profile, improving therapeutic outcomes. As precision medicine continues to gain traction, the demand for radiopharmaceuticals that can provide personalized, targeted treatment is expected to grow significantly.

5. Aging Global Population: The global aging population is contributing to increased demand for targeted radiopharmaceuticals, particularly for cancer and neurodegenerative diseases. Older individuals are more prone to conditions that can be treated with radiopharmaceuticals, driving market growth. This demographic shift is expected to continue expanding the patient base for targeted therapies.

Challenges in the targeted radiopharmaceutical market are:

1. High Costs of Production: One of the main challenges facing the market is the high cost of production for radiopharmaceuticals. Manufacturing these complex compounds, particularly the radioisotopes, requires specialized equipment and facilities, which can be expensive. Additionally, the costs of transporting and handling radioactive materials add to the overall expense, limiting access to these treatments in lower-income regions.

2. Limited Availability of Radioisotopes: The production of radioisotopes is often limited by availability and infrastructure. Short-lived isotopes require rapid and specialized manufacturing processes, which can lead to supply shortages. This issue is compounded by geopolitical factors, as the production of key isotopes like Technetium-99m is concentrated in a few regions, posing risks to global supply chains.

3. Regulatory Hurdles and Market Entry Barriers: Although regulatory support is generally improving, navigating the regulatory environment for new radiopharmaceuticals can still be challenging. Each country has its own set of regulations, and achieving international approval can be a time-consuming and expensive process. These hurdles can delay market entry and hinder the rapid commercialization of new radiopharmaceuticals.

The drivers such as technological advancements, increasing cancer rates, and regulatory support are propelling the market forward. However, challenges related to cost, supply limitations, and regulatory complexities must be addressed to ensure sustainable growth. Overcoming these obstacles will be critical for the widespread adoption of targeted radiopharmaceuticals in the future.

List of Targeted Radiopharmaceutical Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted radiopharmaceutical companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted radiopharmaceutical companies profiled in this report include-

  • Novartis
  • Bayer
  • Lantheus
  • Institute For Radioelements
  • Radiomedix
  • Curium Pharma
  • Clarity Pharmaceuticals

Targeted Radiopharmaceutical Market by Segment

The study includes a forecast for the global targeted radiopharmaceutical market by type, application, and region.

Targeted Radiopharmaceutical Market by Type [Value from 2019 to 2031]:

  • Targeted Therapeutic Radiopharmaceutical
  • Targeted Diagnostic Radiopharmaceutical

Targeted Radiopharmaceutical Market by Application [Value from 2019 to 2031]:

  • Targeted Therapy
  • Targeted Diagnosis

Targeted Radiopharmaceutical Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Targeted Radiopharmaceutical Market

The targeted radiopharmaceutical market has been rapidly evolving, with significant advancements in therapeutic and diagnostic radiopharmaceuticals. These compounds, which combine the precision of targeting specific disease sites with the power of radioactive isotopes, have gained momentum due to their ability to treat conditions like cancer with reduced side effects compared to traditional therapies. This sector is experiencing technological innovation, increased regulatory support, and growing healthcare demand. The United States, China, Germany, India, and Japan are key players driving these developments, each contributing to the global landscape with their unique approaches and market dynamics.

  • United States: The U.S. is a global leader in the targeted radiopharmaceutical market, with recent developments driven by increasing FDA approvals and technological advancements. Innovations such as the approval of Pluvicto (177Lu-PSMA-617) for prostate cancer therapy mark significant milestones. Investment in radiopharmaceuticals for oncology is expanding, with numerous clinical trials underway. Additionally, the U.S. is fostering research in theranostics, combining diagnostic and therapeutic properties in a single agent. Major pharmaceutical companies are focusing on developing advanced radiopharmaceuticals, leveraging AI and precision medicine to improve outcomes and reduce side effects.
  • China: China is rapidly emerging as a significant player in the targeted radiopharmaceutical market, supported by large-scale investments in both public and private sectors. The country's focus on oncology treatments is reflected in its growing number of clinical trials and regulatory approvals. In particular, China's state-run institutions and biotechnology firms are accelerating research into novel radiopharmaceuticals. The government's "Made in China 2025" initiative is pushing for innovation in the life sciences, which includes radiopharmaceutical production. Additionally, the Chinese healthcare system is embracing personalized medicine, which complements the development of targeted therapies, further driving growth.
  • Germany: Germany is home to several leading radiopharmaceutical companies and plays a pivotal role in Europe's radiopharmaceutical market. The country is focused on advancing its nuclear medicine capabilities, particularly in the field of cancer treatment. With a robust regulatory framework, Germany has facilitated the development of radiopharmaceuticals that are now being used in personalized treatments. Key institutions are collaborating on the development of radiopharmaceuticals for both diagnostic and therapeutic purposes, especially in the oncology field. Furthermore, Germany's strong research institutions are pushing boundaries in medical imaging and radioisotope production, which is propelling the market.
  • India: India has seen substantial growth in the targeted radiopharmaceutical sector, driven by an increasing demand for affordable cancer therapies. The country is establishing itself as a key hub for radiopharmaceutical production, particularly for diagnostic radiopharmaceuticals. With advancements in production technology, Indian companies are improving the availability of key isotopes like Technetium-99m. Research into new therapeutic applications for targeted radiopharmaceuticals, especially for cancer and neurological disorders, is gaining momentum. The government is also focused on strengthening the regulatory framework, making it easier for new treatments to enter the market and reach patients.
  • Japan: Japan remains a leader in the development of advanced targeted radiopharmaceuticals, particularly in nuclear medicine. Recent developments focus on integrating radiopharmaceuticals with diagnostic imaging to offer combined therapy options, a field known as theranostics. Japan's strong collaboration between academia, government, and industry fosters cutting-edge research and innovation. Notably, Japan has pioneered the development of radiopharmaceuticals for rare and complex cancers, such as neuroendocrine tumors. The country's highly advanced healthcare system and its regulatory approach support rapid adoption of new treatments, positioning Japan as a hub for radiopharmaceutical innovation in Asia.

Features of the Global Targeted Radiopharmaceutical Market

  • Market Size Estimates: Targeted radiopharmaceutical market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Targeted radiopharmaceutical market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Targeted radiopharmaceutical market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeted radiopharmaceutical market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted radiopharmaceutical market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the targeted radiopharmaceutical market by type (targeted therapeutic radiopharmaceutical and targeted diagnostic radiopharmaceutical), application (targeted therapy and targeted diagnosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Targeted Radiopharmaceutical Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Targeted Therapeutic Radiopharmaceutical: Trends and Forecast (2019-2031)
  • 4.4 Targeted Diagnostic Radiopharmaceutical: Trends and Forecast (2019-2031)

5. Global Targeted Radiopharmaceutical Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Targeted Therapy: Trends and Forecast (2019-2031)
  • 5.4 Targeted Diagnosis: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Targeted Radiopharmaceutical Market by Region

7. North American Targeted Radiopharmaceutical Market

  • 7.1 Overview
  • 7.4 United States Targeted Radiopharmaceutical Market
  • 7.5 Mexican Targeted Radiopharmaceutical Market
  • 7.6 Canadian Targeted Radiopharmaceutical Market

8. European Targeted Radiopharmaceutical Market

  • 8.1 Overview
  • 8.4 German Targeted Radiopharmaceutical Market
  • 8.5 French Targeted Radiopharmaceutical Market
  • 8.6 Spanish Targeted Radiopharmaceutical Market
  • 8.7 Italian Targeted Radiopharmaceutical Market
  • 8.8 United Kingdom Targeted Radiopharmaceutical Market

9. APAC Targeted Radiopharmaceutical Market

  • 9.1 Overview
  • 9.4 Japanese Targeted Radiopharmaceutical Market
  • 9.5 Indian Targeted Radiopharmaceutical Market
  • 9.6 Chinese Targeted Radiopharmaceutical Market
  • 9.7 South Korean Targeted Radiopharmaceutical Market
  • 9.8 Indonesian Targeted Radiopharmaceutical Market

10. ROW Targeted Radiopharmaceutical Market

  • 10.1 Overview
  • 10.4 Middle Eastern Targeted Radiopharmaceutical Market
  • 10.5 South American Targeted Radiopharmaceutical Market
  • 10.6 African Targeted Radiopharmaceutical Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Targeted Radiopharmaceutical Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Novartis
    • Company Overview
    • Targeted Radiopharmaceutical Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Bayer
    • Company Overview
    • Targeted Radiopharmaceutical Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Lantheus
    • Company Overview
    • Targeted Radiopharmaceutical Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Institute For Radioelements
    • Company Overview
    • Targeted Radiopharmaceutical Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Radiomedix
    • Company Overview
    • Targeted Radiopharmaceutical Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Curium Pharma
    • Company Overview
    • Targeted Radiopharmaceutical Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Clarity Pharmaceuticals
    • Company Overview
    • Targeted Radiopharmaceutical Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Targeted Radiopharmaceutical Market
  • Figure 2.1: Usage of Targeted Radiopharmaceutical Market
  • Figure 2.2: Classification of the Global Targeted Radiopharmaceutical Market
  • Figure 2.3: Supply Chain of the Global Targeted Radiopharmaceutical Market
  • Figure 2.4: Driver and Challenges of the Targeted Radiopharmaceutical Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Targeted Radiopharmaceutical Market ($B) by Type
  • Figure 4.3: Forecast for the Global Targeted Radiopharmaceutical Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Targeted Therapeutic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Targeted Diagnostic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 5.1: Global Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Targeted Radiopharmaceutical Market ($B) by Application
  • Figure 5.3: Forecast for the Global Targeted Radiopharmaceutical Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Targeted Therapy in the Global Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Targeted Diagnosis in the Global Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 6.1: Trends of the Global Targeted Radiopharmaceutical Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Targeted Radiopharmaceutical Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 7.2: North American Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 8.2: European Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
  • Figure 8.5: European Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 9.2: APAC Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Targeted Radiopharmaceutical Market (2019-2031)
  • Figure 10.2: ROW Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Targeted Radiopharmaceutical Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Targeted Radiopharmaceutical Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Targeted Radiopharmaceutical Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Targeted Radiopharmaceutical Market by Type
  • Figure 12.2: Growth Opportunities for the Global Targeted Radiopharmaceutical Market by Application
  • Figure 12.3: Growth Opportunities for the Global Targeted Radiopharmaceutical Market by Region
  • Figure 12.4: Emerging Trends in the Global Targeted Radiopharmaceutical Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Targeted Radiopharmaceutical Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Targeted Radiopharmaceutical Market by Region
  • Table 1.3: Global Targeted Radiopharmaceutical Market Parameters and Attributes
  • Table 3.1: Trends of the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 3.2: Forecast for the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Targeted Radiopharmaceutical Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 4.4: Trends of Targeted Therapeutic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 4.5: Forecast for Targeted Therapeutic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 4.6: Trends of Targeted Diagnostic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 4.7: Forecast for Targeted Diagnostic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Targeted Radiopharmaceutical Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 5.4: Trends of Targeted Therapy in the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 5.5: Forecast for Targeted Therapy in the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 5.6: Trends of Targeted Diagnosis in the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 5.7: Forecast for Targeted Diagnosis in the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Targeted Radiopharmaceutical Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Targeted Radiopharmaceutical Market (2025-2031)
  • Table 7.1: Trends of the North American Targeted Radiopharmaceutical Market (2019-2024)
  • Table 7.2: Forecast for the North American Targeted Radiopharmaceutical Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Targeted Radiopharmaceutical Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Targeted Radiopharmaceutical Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Targeted Radiopharmaceutical Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Targeted Radiopharmaceutical Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Targeted Radiopharmaceutical Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Targeted Radiopharmaceutical Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Targeted Radiopharmaceutical Market (2019-2031)
  • Table 8.1: Trends of the European Targeted Radiopharmaceutical Market (2019-2024)
  • Table 8.2: Forecast for the European Targeted Radiopharmaceutical Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Targeted Radiopharmaceutical Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Targeted Radiopharmaceutical Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Targeted Radiopharmaceutical Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Targeted Radiopharmaceutical Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Targeted Radiopharmaceutical Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Targeted Radiopharmaceutical Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Targeted Radiopharmaceutical Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Targeted Radiopharmaceutical Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Targeted Radiopharmaceutical Market (2019-2031)
  • Table 9.1: Trends of the APAC Targeted Radiopharmaceutical Market (2019-2024)
  • Table 9.2: Forecast for the APAC Targeted Radiopharmaceutical Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Targeted Radiopharmaceutical Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Targeted Radiopharmaceutical Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Targeted Radiopharmaceutical Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Targeted Radiopharmaceutical Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Targeted Radiopharmaceutical Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Targeted Radiopharmaceutical Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Targeted Radiopharmaceutical Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Targeted Radiopharmaceutical Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Targeted Radiopharmaceutical Market (2019-2031)
  • Table 10.1: Trends of the ROW Targeted Radiopharmaceutical Market (2019-2024)
  • Table 10.2: Forecast for the ROW Targeted Radiopharmaceutical Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Targeted Radiopharmaceutical Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Targeted Radiopharmaceutical Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Targeted Radiopharmaceutical Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Targeted Radiopharmaceutical Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Targeted Radiopharmaceutical Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Targeted Radiopharmaceutical Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Targeted Radiopharmaceutical Market (2019-2031)
  • Table 11.1: Product Mapping of Targeted Radiopharmaceutical Suppliers Based on Segments
  • Table 11.2: Operational Integration of Targeted Radiopharmaceutical Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Targeted Radiopharmaceutical Revenue
  • Table 12.1: New Product Launches by Major Targeted Radiopharmaceutical Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Targeted Radiopharmaceutical Market